125 related articles for article (PubMed ID: 8096954)
1. Management of malignant teratoma: does referral to a specialist unit matter?
Harding MJ; Paul J; Gillis CR; Kaye SB
Lancet; 1993 Apr; 341(8851):999-1002. PubMed ID: 8096954
[TBL] [Abstract][Full Text] [Related]
2. Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours?
Harding M; Paul J; Kaye SB
Br J Urol; 1995 Oct; 76(4):491-4. PubMed ID: 7551890
[TBL] [Abstract][Full Text] [Related]
3. Should we still advocate referral to specialist centres for teratoma?
Hughes MJ; Kaye SB
Eur J Cancer; 1995; 31A(3):291-2. PubMed ID: 7786591
[No Abstract] [Full Text] [Related]
4. Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists.
Clarke K; Howard GC; Elia MH; Hutcheon AW; Kaye SB; Windsor PM; Yosef HM
Br J Cancer; 1995 Nov; 72(5):1300-2. PubMed ID: 7577486
[TBL] [Abstract][Full Text] [Related]
5. Results of treatment of non seminomatous germ cell tumours; 122 consecutive cases in the West of Scotland, 1981-1985.
Graham J; Harding M; Mill L; Kerr DJ; Rankin E; Calman KC; Kaye SB
Br J Cancer; 1988 Feb; 57(2):182-5. PubMed ID: 3358908
[TBL] [Abstract][Full Text] [Related]
6. Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.
Funt SA; Patil S; Feldman DR; Motzer RJ; Bajorin DF; Sheinfeld J; Tickoo SK; Reuter VE; Bosl GJ
J Clin Oncol; 2019 Sep; 37(26):2329-2337. PubMed ID: 31233353
[TBL] [Abstract][Full Text] [Related]
7. Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours.
Hatton MQ; Paul J; Harding M; MacFarlane G; Robertson AG; Kaye SB
Eur J Cancer; 1995; 31A(9):1487-91. PubMed ID: 7577077
[TBL] [Abstract][Full Text] [Related]
8. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration.
Kildahl-Andersen A; Erke MG; Sagstuen H; Bremnes RM
Acta Oncol; 2005; 44(6):537-44. PubMed ID: 16165912
[TBL] [Abstract][Full Text] [Related]
9. Testicular germ cell tumors in boys <10 years: results of the protocol MAHO 98 in respect to surgery and watch & wait strategy.
Göbel U; Haas R; Calaminus G; Botorek P; Schmidt P; Teske C; Schönberger S; Schneider DT; Harms D
Klin Padiatr; 2013 Nov; 225(6):296-302. PubMed ID: 24158884
[TBL] [Abstract][Full Text] [Related]
10. An analysis of surveillance for stage I combined teratoma--seminoma of the testis.
Thomas R; Dearnaley D; Nicholls J; Norman A; Sampson S; Horwich A
Br J Cancer; 1996 Jul; 74(1):59-62. PubMed ID: 8679458
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
12. Non-seminomatous germ cell testis cancer in Ireland (1980-1985). Management, results and prognostic variables with relevance to national management protocols.
Thornhill JA; Walsh A; Kelly D; Fennelly JJ; Fitzpatrick JM
Eur Urol; 1988; 15(1-2):84-8. PubMed ID: 3215241
[TBL] [Abstract][Full Text] [Related]
13. The treatment of poor risk nonseminomatous testicular tumors.
Pontes JE; Wajsman Z; Huben RP
J Urol; 1984 Mar; 131(3):494-6. PubMed ID: 6699989
[TBL] [Abstract][Full Text] [Related]
14. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal.
Necchi A; Colecchia M; Nicolai N; Piva L; Catanzaro M; Biasoni D; Torelli T; Stagni S; Paolini B; Milani A; Salvioni R
BJU Int; 2011 Apr; 107(7):1088-94. PubMed ID: 20868391
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
16. Modern management for testicular teratoma.
Read G
Br J Hosp Med; 1996 Sep 4-17; 56(5):218-21. PubMed ID: 8879701
[No Abstract] [Full Text] [Related]
17. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
18. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
19. A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists.
Howard GC; Clarke K; Elia MH; Hutcheon AW; Kaye SB; Windsor PM; Yosef HM; Sharp L
Br J Cancer; 1995 Nov; 72(5):1307-11. PubMed ID: 7577488
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
